Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Keep an Eye on These 4 High-Flying Stocks Today

Page 1 of 2

U.S stocks have started the week on a slightly positive note, but are finding it difficult to stay in green territory, with Asian markets having slumped again and European indices having closed lower as well. There are, however, certain stocks that have not followed the overall trend and have registered solid gains during the first hours of trading today. Among those stocks are Anavex Life Sciences Corp. (NASDAQ:AVXL), NorthStar Asset Management Group Inc (NYSE:NSAM), Affymetrix, Inc. (NASDAQ:AFFX) and Acorn International, Inc. (ADR) (NYSE:ATV). Let’s find out what is driving these stocks higher today and what elite hedge funds think of them.

We track hedge funds and prominent investors because our research has shown that historically their stock picks delivered superior risk-adjusted returns. This is especially true in the small-cap space. The 50 most popular large-cap stocks among hedge funds had a monthly alpha of about six basis points per month between 1999 and 2012; however the 15 most popular small-cap stocks delivered a monthly alpha of 80 basis points during the same period. This means investors would have generated 10 percentage points of alpha per year simply by imitating hedge funds’ top 15 small-cap ideas (see the details here).

Anavex Life Sciences Corp. (NASDAQ:AVXL) is trending higher this morning on positive news related to one of its product candidates. In a press release today, the company announced the results from an interim analysis that point to positive effects from its ANAVEX 2-73 drug candidate. Anavex’s CEO expressed his delight with the results and affirmed the company’s desire to further develop the testing of the drug. Shares have jumped by as much as 26% during the first hour of trading and are currently up by just under 9%.

Follow Anavex Life Sciences Corp. (OTCMKTS:AVXL)
Trade (OTCMKTS:AVXL) Now!

None of the hedge funds tracked by Insider Monkey reported holding a stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) as of the end of the third quarter of 2015.

With NorthStar Asset Management Group Inc (NYSE:NSAM) down by more than 50% from its 2015 high, management has decided to look for ways to increase shareholder value, having hired Goldman Sachs Group Inc (NYSE:GS) as a financial adviser.

“We believe our current share price undervalues the Company. Our Board of Directors and management have always been committed to acting in the best interests of our shareholders and we are aggressively seeking ways to maximize shareholder value,” said David Hamamoto, NortStar’s Chairman.

Follow Northstar Asset Management Group Inc. (NYSE:NSAM)
Trade (NYSE:NSAM) Now!

NorthStar Asset Management Group Inc (NYSE:NSAM) lost some of the support of top investors during the third quarter of 2015, with the number of hedge funds long the stock dropping to 56, from 63 at the end of June. Still, hedge funds have a notable presence among the company’s shareholders, having control over 48.5% of the company’s common stock. Robert Pitts is betting big on the stock, having pledged more than 4% of his capital to his position in it. In its latest 13F filling, Steadfast Capital Management reported ownership of 14.5 million NorthStar shares, up by 1% over the third quarter.

We look into the latest action on Affymetrix and Acorn International on the next page.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!